Hepatitis C: Clinical Trials

32 trials for Hepatitis C, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 unknown. 32 Phase 2, 7 Phase 3, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 232Unknown 32
Phase 37Unknown 7
Phase 15Unknown 5

Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
Glecaprevir/pibrentasvir, Placebo - PTSD
Phase 2 / Phase 3UnknownWhite River Junction Veterans Affairs Medical Center922023-12-182025-04-24
Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).
Prolonged-Release Pirfenidone - Liver Cirrhosis, Hepatitis C, Chronic
Phase 2UnknownUniversity of Guadalajara602019-08-012023-07-06
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients
Seraprevir, Sofosbuvir - Hepatitis C Virus Infection
Phase 2UnknownGinkgopharma CO., LTD362019-04-032019-10-01
SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic
Phase 2 / Phase 3UnknownNanjing Sanhome Pharmaceutical, Co., Ltd.4402019-03-292019-08-28
Outcomes Mandate National Integration With Cannabis as Medicine
Cannabis, Medical, RYAH-Medtech Inhaler - Chronic Pain, Chronic Pain Syndrome
Phase 2UnknownOMNI Medical Services, LLC2000002018-12-012022-06-02
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
Ledipasvir and sofosbuvir - Indolent Lymphoma
Phase 2UnknownNational Taiwan University Hospital212017-09-012017-08-25
Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients
Ombitasvir, Paritaprevir and Ritonavir - Chronic Hepatitis c
Phase 2UnknownAin Shams University402016-11-092018-01-18
Strategic Transformation of the Market of HCV Treatments
sofosbuvir + ravidasvir - Hepatitis C
Phase 2 / Phase 3UnknownDrugs for Neglected Diseases6032016-09-012021-01-20
Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV Hepatitis
Mesenchymal Stem Cells - Liver Cirrhosis
Phase 1 / Phase 2UnknownSaglik Bilimleri Universitesi Gulhane Tip Fakultesi52016-01-012016-06-07
A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
ravidasvir hydrochloride, sofosbuvir, ribavirin - Chronic Hepatitis C
Phase 2 / Phase 3UnknownPharco Pharmaceuticals3002015-01-012016-04-07
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets), Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection, Rebetol® (ribavirin), 1000/1200mg by mouth daily - Chronic Hepatitis C
Phase 2UnknownSt Vincent's Hospital Melbourne302013-09-012013-09-24
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
Miravirsen, Telaprevir, Ribavirin - Hepatitis C, Chronic
Phase 2UnknownSantaris Pharma A/S202013-06-012014-11-18
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor
1- Erlotinib, placebo - Chronic Hepatitis C Infection, HCV Genotype 1b
Phase 1 / Phase 2UnknownUniversity Hospital, Strasbourg, France122013-05-012014-06-17
Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C
Miravirsen sodium - Hepatitis C
Phase 2UnknownSantaris Pharma A/S102012-11-012014-01-06
Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance
metformin, pegylated-IFN, ribavirin - Chronic Hepatitis c, Insulin Resistance
Phase 2 / Phase 3UnknownKaohsiung Veterans General Hospital.1202012-08-012012-08-14
Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
Rifaximin, Placebo - Hepatitis C
Phase 2UnknownColumbia University592012-03-012016-04-22
BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C
BIP 48 (Peginterferon alfa 2b 48kDA), Peginterferon alfa 2a 40kDA - Chronic Hepatitis C
Phase 2 / Phase 3UnknownThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)7402012-01-012012-06-20
Effects of Vitamin D on Inflammation in Liver Disease
Vitamin D, Placebo - Hepatitis C Infection, Vitamin D Deficiency
Phase 2UnknownVeterans Medical Research Foundation242011-11-012012-12-21
Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects
anti-CD3 monoclonal antibody, Sodium Chloride placebo - Chronic Hepatitis C
Phase 2UnknownInspira Medical AB362011-11-012011-10-25
CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects
ChronVac-C + SOC, SOC - Chronic Hepatitis C
Phase 2UnknownChronTech Pharma AB322011-04-012011-10-12

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Hepatitis C, Chronic (17)  ·  Liver Cirrhosis (3)  ·  Liver Diseases (3)  ·  Virus Diseases (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Depression (2)  ·  Hepatitis (2)  ·  Hepatitis, Chronic (2)  ·  Stress Disorders, Post-Traumatic (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Anemia, Sickle Cell (1)  ·  Anxiety Disorders (1)  ·  Autistic Disorder (1)  ·  Bipolar Disorder (1)

Broader conditions

Blood-Borne Infections (32)  ·  Communicable Diseases (32)  ·  Digestive System Diseases (32)  ·  Flaviviridae Infections (32)  ·  Hepatitis, Viral, Human (32)  ·  RNA Virus Infections (32)  ·  Infections (31)  ·  Hepatitis (30)  ·  Liver Diseases (29)  ·  Virus Diseases (29)  ·  Pathologic Processes (23)  ·  Pathological Conditions, Signs and Symptoms (23)  ·  Chronic Disease (20)  ·  Disease Attributes (20)  ·  Hepatitis, Chronic (17)

Interventions

Ribavirin (8)  ·  peginterferon alfa-2a (4)  ·  Sofosbuvir (3)  ·  Interleukin-7 (2)  ·  Rifaximin (2)  ·  miravirsen (2)  ·  peginterferon alfa-2b (2)  ·  ravidasvir (2)  ·  Fatty Acids, Omega-3 (1)  ·  Hydroxychloroquine (1)  ·  Hymecromone (1)  ·  Medical Marijuana (1)  ·  Metformin (1)  ·  N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (1)  ·  Pharmaceutical Preparations (1)

Sponsors

Cytheris SA (2)  ·  Santaris Pharma A/S (2)  ·  Ain Shams University (1)  ·  BioGeneric Pharma (1)  ·  BioWest Therapeutics Inc (1)  ·  Bnai Zion Medical Center (1)  ·  ChronTech Pharma AB (1)  ·  Columbia University (1)  ·  Drugs for Neglected Diseases (1)  ·  Ginkgopharma CO., LTD (1)  ·  Hepasome Pharmaceuticals (1)  ·  Inspira Medical AB (1)  ·  Kaohsiung Veterans General Hospital. (1)  ·  MTmedical Institute of Health (1)  ·  Nanjing Sanhome Pharmaceutical, Co., Ltd. (1)

Countries

United States (9)  ·  Egypt (3)  ·  France (3)  ·  Puerto Rico (3)  ·  Australia (2)  ·  Austria (2)  ·  Canada (2)  ·  China (2)  ·  Italy (2)  ·  Poland (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Brazil (1)  ·  Germany (1)  ·  India (1)

Top investigators

Alexander Thompson, MBBS (1)  ·  Amanda Quevedo, Sub Coord (1)  ·  Anastacio M Hoyumpa, Prof. M.D. (1)  ·  Anders G Vahlne, Professor (1)  ·  Bradley V Watts, MD, MPH (1)  ·  Charles T Leach, Prof. M.D. (1)  ·  Daiana V. Gomes, AssitSocial (1)  ·  Dharmesh Kapoor, MD (1)  ·  Dr Catherine Mutter, MD (1)  ·  Dr Samira Fafi-Kremer, Pharma D, PhD (1)  ·  Dr. Ryan O Lakin, MD JD (1)  ·  Dubravko Pavlin, PhD (1)

Results publications

PMID 24876849, PMID 25042797, PMID 25043197, PMID 26006200, PMID 28935432, PMID 33865507, PMID 34307188, PMID 35080256, PMID 37055910, PMID 37856013, PMID 41044745

NIH funding

2009 (1)